🔗 Share this article

Former Prime Minister Rishi Sunak has reinforced his appeal for a targeted screening programme for prostate gland cancer.

During a recent conversation, he stated being "convinced of the immediate need" of introducing such a system that would be affordable, deliverable and "preserve countless lives".

These remarks emerge as the UK National Screening Committee reevaluates its decision from five years ago not to recommend regular testing.

News sources suggest the authority may continue with its present viewpoint.

Athlete Adds Voice to Campaign

Olympic cycling champion Chris Hoy, who has advanced prostate cancer, advocates for middle-aged males to be tested.

He proposes reducing the eligibility age for requesting a PSA blood screening.

Currently, it is not automatically provided to healthy individuals who are under 50.

The prostate-specific antigen screening is debated however. Measurements can rise for causes apart from cancer, such as bacterial issues, causing false positives.

Skeptics argue this can result in unwarranted procedures and side effects.

Targeted Screening Initiative

The suggested testing initiative would focus on males between 45 and 69 with a family history of prostate cancer and black men, who face double the risk.

This population encompasses around 1.3 million individuals males in the United Kingdom.

Research projections suggest the system would cost twenty-five million pounds per year - or about £18 per person per patient - comparable to colorectal and mammary cancer screening.

The assumption includes one-fifth of eligible men would be contacted annually, with a 72% uptake rate.

Medical testing (imaging and tissue samples) would need to increase by 23%, with only a reasonable increase in healthcare personnel, based on the analysis.

Medical Professionals Reaction

Several clinical specialists remain sceptical about the benefit of testing.

They assert there is still a chance that men will be treated for the disease when it is potentially overtreated and will then have to live with side effects such as incontinence and sexual performance issues.

One prominent urology specialist commented that "The issue is we can often identify abnormalities that may not require to be managed and we risk inflicting harm...and my apprehension at the moment is that risk to reward ratio isn't quite right."

Individual Experiences

Individual experiences are also influencing the discussion.

One case features a 66-year-old who, after asking for a PSA test, was diagnosed with the cancer at the age of 59 and was informed it had metastasized to his pelvis.

He has since undergone chemo treatment, beam therapy and endocrine treatment but remains incurable.

The patient supports examination for those who are at higher risk.

"This is crucial to me because of my sons – they are approaching middle age – I want them screened as promptly. If I had been tested at 50 I am sure I wouldn't be in the circumstances I am currently," he said.

Future Actions

The National Screening Committee will have to evaluate the data and viewpoints.

Although the latest analysis indicates the consequences for personnel and accessibility of a testing initiative would be achievable, others have maintained that it would take diagnostic capabilities from patients being treated for other conditions.

The ongoing discussion emphasizes the complex balance between timely diagnosis and possible overtreatment in prostate gland cancer care.